Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.46 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | MC1R | Q01726 | 1/20 | 0.43 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21579283 | 0.90 | NTMT1 (0.47) | OPRD1OPRM1 | |
| SCHEMBL21571000 | 0.87 | NMUR2 (0.52) | NMUR2NMUR1OPRD1OPRM1C5AR1 | |
| SCHEMBL21579357 | 0.87 | NMUR2 (0.52) | NMUR2NMUR1OPRD1OPRM1C5AR1 | |
| SCHEMBL21570976 | 0.86 | NTMT1 (0.51) | OPRD1OPRM1 | |
| SCHEMBL21570970 | 0.86 | NTMT1 (0.51) | OPRD1OPRM1 | |
| SCHEMBL21571015 | 0.86 | NTMT1 (0.51) | OPRD1OPRM1 | |
| SCHEMBL21579316 | 0.86 | NTMT1 (0.51) | OPRD1OPRM1 | |
| SCHEMBL21570973 | 0.86 | NTMT1 (0.51) | OPRD1OPRM1 | |
| SCHEMBL21570988 | 0.82 | OPRM1 (0.48) | OPRD1OPRM1 | |
| SCHEMBL21570990 | 0.82 | OPRM1 (0.48) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352338-A1 | INHIBITORS FOR PROTEIN N-TERMINAL METHYLTRANSFERASE AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352338-A1 | INHIBITORS FOR PROTEIN N-TERMINAL METHYLTRANSFERASE AND USES THEREOF | GNMT, PRMT1, PRMT5 | NMUR2 2597/4885NMUR1 2287/4885OPRD1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.